Financials data is unavailable for this security.
View more
Year on year Taiyen Biotech Co Ltd 's revenues fell -5.67% from 3.61bn to 3.41bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 426.70m to 300.39m, a -29.60% decrease.
| Gross margin | 41.39% |
|---|---|
| Net profit margin | 8.77% |
| Operating margin | 10.24% |
| Return on assets | 3.46% |
|---|---|
| Return on equity | 5.59% |
| Return on investment | 4.11% |
More ▼
Cash flow in TWDView more
In 2023, cash reserves at Taiyen Biotech Co Ltd fell by 84.36m. However, the company earned 454.54m from its operations for a Cash Flow Margin of 13.33%. In addition the company used 339.30m on investing activities and also paid 199.22m in financing cash flows.
| Cash flow per share | 2.39 |
|---|---|
| Price/Cash flow per share | 14.83 |
| Book value per share | 32.28 |
|---|---|
| Tangible book value per share | 32.23 |
More ▼
Balance sheet in TWDView more
| Current ratio | 2.44 |
|---|---|
| Quick ratio | 2.13 |
| Total debt/total equity | 0.0383 |
|---|---|
| Total debt/total capital | 0.0367 |
More ▼
Growth rates in TWD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -20.00% and -29.54%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 4.28% |
|---|---|
| Div growth rate (5 year) | -7.79% |
| Payout ratio (TTM) | 66.97% |
| EPS growth(5 years) | -7.86 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -10.04 |
More ▼
